Results 271 to 280 of about 134,036 (314)

Drug interactions with angiotensin receptor blockers

Expert Opinion on Drug Safety, 2005
Many patients with high blood pressure receive multiple medications for hypertension and other conditions, placing them at risk for adverse drug interactions. Additionally, as the prevalence of hypertension increases with age, factors like greater frailty, comorbidity of the elderly requiring polypharmacy, and reduced hepatic and renal clearance rates ...
Steffen, Böhler, David, Pittrow, Peter, Bramlage, Wilhelm, Kirch   +3 more
openaire   +2 more sources

Angiotensin-II Receptor Blockers

2000
As described in the previous chapter, the renin-angiotensin system (RAS) plays an important role in the body’s regulation of arterial blood pressure. The effector hormone of the RAS is angiotensin II, which maintains the systemic vascular resistance and extracellular fluid volume through its direct and indirect vasoconstrictive and blood volume ...
William H. Frishman, Angela Cheng-Lai, Julie Chen   +2 more
openaire   +1 more source

Angiotensin II Receptor Blockers

2014
The angiotensin II receptor blockers (ARBs) inhibit the activity of angiotensin II at the angiotensin II receptor level (AT-1, AT-2 receptors). Losartan potassium is the prototype of the ARBs. Others are candesartan, irbesartan, valsartan, telmisartan, olmesartan, eprosartan, and azilsartan.
Esen Özkaya, Kurtuluş Didem Yazganoğlu   +1 more
openaire   +1 more source

Angiotensin receptor blockers and angiotensin receptor–neprilysin inhibitors

2022
Abstract This chapter addresses angiotensin receptor blockers (ARBs) and angiotensin receptor–neprilysin inhibitors (ARNIs). ARBs or angiotensin II receptor antagonists were introduced as a potentially superior alternative to an angiotensin converting enzyme (ACE) inhibitor and, later, as a possible addition to an ACE inhibitor.
openaire   +1 more source

Angiotensin receptor blockers in diabetic nephropathy

Current Diabetes Reports, 2001
Where shall we place angiotensin receptor blockers in the scheme of the prevention of diabetic nephropathy? Only the results of a large, randomized double-blind trial with a comparable and appropriate alternative would prove therapeutic efficacy. The results of several trials with angiotensin-converting enzyme (ACE) inhibitors have proven them to be ...
D A, Price, N K, Hollenberg
openaire   +2 more sources

Fimasartan: A New Angiotensin Receptor Blocker

Drugs, 2016
Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one derivative of losartan with the imidazole ring replaced, which enables higher potency and longer duration than losartan. Fecal elimination and biliary excretion are the predominant elimination pathways of
Hae-Young, Lee, Byung-Hee, Oh
openaire   +2 more sources

Angiotensin receptor blockers

2011
Angiotensin receptor blockers (ARBs) were developed to providean alternative approach to interrupting the renin–angiotensin system(RAS), which was pharmacologically distinct from that ofangiotensin converting enzyme (ACE) inhibitors. By selectivelyblocking the angiotensin II type 1 (AT1) receptor, ARBs werethought to offer the potential for more ...
openaire   +1 more source

Angiotensin receptor blockers following acute stroke

Expert Review of Cardiovascular Therapy, 2011
Elevated blood pressure during the acute stroke period is associated with poor neurologic outcomes; however, treating blood pressure in this setting remains controversial. Interest in modulating the renin-angiotensin system in this setting has gained momentum because of neurohormonal properties, which may provide benefits beyond blood pressure control.
Denise H, Rhoney, Lynette R, Moser
openaire   +2 more sources

Angiotensin II Receptor Blockers

2001
The angiotensin II (Ang II) receptor antagonists are the most selective blockers of the renin-angiotensin system (RAS) currently available. The efficacy of these drugs is similar to that of the other major antihypertensive drug classes, but they appear to exhibit fewer side effects. Angiotensin receptor blockers (ARBs) selectively block the angiotensin
openaire   +1 more source

Vascular benefits of angiotensin receptor blockers

Expert Opinion on Investigational Drugs, 2007
There is convincing evidence that angiotensin II, through activation of the angiotensin II type 1 (AT1) receptor, is involved in the atherosclerotic process. Similarly, angiotensin receptor blockers decrease vascular inflammation, hypertrophy and thrombosis, which are the key components of the progression of atherosclerosis.
openaire   +2 more sources